Nuvectis Pharma, Inc. Profile

Industry

Biotechnology

Sector

Healthcare

Number of Employees

Nuvectis Pharma Common Stock's Business Model

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

About Nuvectis Pharma Common Stock

Website: https://www.nuvectis.com

CEO (Chief Executive Officer): Mr. Ron Bentsur M.B.A.

IPO date: 2022-02-04

Contact

Country: US

Address: 1 Bridge Plaza

City: Fort Lee

State: NJ

Phone: 201 614 3150

Zip Code: 07024

Other

CIK: 0001875558

ISIN: US67080T1088

CUSIP: 67080T108

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.